BIO Asia–Taiwan 2026

The Australian Advantage for Biotechs

Recognised as a leading early-phase CRO in Australia, Avance Clinical supports biotechs with fast, globally aligned early-phase development pathways. Australia’s clinical research environment provides several unique advantages, including:

• Fast ethics approvals with first-patient-in possible in 5 to 6 weeks
• No IND requirement, reducing early regulatory burden
• Up to 43.5% R&D tax rebate on eligible clinical trial costs
• Access to world-class clinical sites and highly experienced investigators
• High-quality data accepted by global regulators including the TGA, FDA, EMA, and MHRA

Avance Clinical leverages these advantages to help biotechs reach proof-of-concept sooner, manage costs effectively, and transition smoothly into global later-phase programs.